Evotec AG Announces the Successful Completion of the First Phase I Study With EVT 401, An Oral P2X7 Receptor Antagonist -- Very Good Safety Profile and Confirmed ‘On Target Activity’

HAMBURG, Germany, June 29, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) today announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401. EVT 401 is a small molecule drug candidate and a potentially novel approach to orally treat inflammatory conditions such as Rheumatoid Arthritis.